| 1 |
29435137 | Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. | 2018 Jan 12 |
1 |
| 2 |
27475932 | Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib. | 2016 Oct 10 |
1 |
| 3 |
24492292 | The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer. | 2014 Mar-Apr |
3 |
| 4 |
23144237 | Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. | 2013 Jan |
1 |